Form 4: Bicycle Therapeutics CFO Executes Non-Discretionary Share Sale for Tax Obligations

Bicycle Therapeutics' Chief Financial Officer, Alethia Young, sold 204 ordinary shares at a weighted average price of $7.09 to cover statutory tax withholding obligations related to restricted stock unit vesting.

Summary

• Alethia Young, Chief Financial Officer of Bicycle Therapeutics PLC (BCYC), reported a transaction involving the sale of ordinary shares.
• The transaction occurred on July 2, 2025, and involved the disposition of 204 ordinary shares.
• The shares were sold at a weighted average price of $7.09, with individual transactions ranging from $7.09 to $7.14 per share.
• Following this transaction, Alethia Young beneficially owns 45,186 ordinary shares directly.
• The sale was a 'sell to cover' transaction, mandated by the reporting person's award agreement to satisfy minimum statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units.
• This sale does not represent a discretionary sale by the reporting person.

Sentiment

Score: 5

Explanation: The transaction is a neutral, non-discretionary 'sell to cover' for tax purposes, which is a standard event for executives receiving equity compensation. It does not indicate a change in management's view of the company's prospects.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• The sale represents the number of shares required to be sold to cover statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units.
• This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary sale by the Reporting Person.

Industry Context

This Form 4 filing details a routine, non-discretionary insider transaction for tax purposes, which is common across all industries when restricted stock units vest. It does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The sale of 204 shares by the CFO is a very small, non-discretionary transaction and is unlikely to have any material impact on the company's share price or shareholder sentiment.

Key Dates

Keywords

Bicycle Therapeutics, BCYC, SEC Form 4, Insider Transaction, Share Sale, Chief Financial Officer, Restricted Stock Units, Tax Withholding, Sell to Cover